Articles and Videos
Loading...
September 21, 2021
How advances in cannabinoid synthesis provide access to rare cannabinoids
In this interview with Shadd Dales of The Dales Report, InMed CEO Eric A. Adams talks about how advances in cannabinoid manufacturing will provide access...
Source:
The Dales Report
September 21, 2021
InMed’s expansion into the health and wellness sector with the recent acquisition of BayMedica
What is InMed’s mission? In this interview with Shadd Dales of The Dales Report, InMed CEO, Eric A. Adams, talks about InMed’s pharmaceutical programs and...
Source:
The Dales Report
September 16, 2021
InMed and BayMedica Host First Webinar Together Following News of Signing Definitive Agreement on Acquisition
InMed and BayMedica hosted a live webinar to talk about InMed's acquisition of BayMedica, how it positions the company as a leader in the manufacturing...
September 14, 2021
BayMedica Acquisition Propels InMed (NASDAQ: INM) Into Leadership Role In Manufacturing & Commercialization of Rare Cannabinoids
Beyond the well-known cannabinoids of THC and CBD, there’s a whole world of rare cannabinoids. Indeed, there are more than 100 rare cannabinoids that have been...
September 13, 2021
Journalist Vivienne Parry Interviews InMed CEO, Eric A. Adams and BayMedica Co-founder, Shane Johnson, to Talk About their Shared Vision for the Combined Company
On September 13th, journalist Vivienne Parry interviewed InMed Pharmaceuticals' President and CEO, Eric A. Adams, and BayMedica's co-founder, Shane Johnson. In their first interview together,...
Source:
Edison TV
September 13, 2021
InMed Pharmaceuticals Inc. Enters Agreement For ‘Transformative’ Acquisition Of Leading Manufacturer Of Rare Cannabinoids
InMed Pharmaceuticals, a leader in the manufacturing and clinical development of rare cannabinoids, has signed a definitive agreement to acquire BayMedica Inc., a private, U.S.-based...